OTCMKTS:BICX Biocorrx Q2 2025 Earnings Report $0.25 0.00 (0.00%) As of 09/10/2026 09:30 AM Eastern ProfileEarnings History Biocorrx EPS ResultsActual EPS-$0.07Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABiocorrx Revenue ResultsActual Revenue$0.18 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABiocorrx Announcement DetailsQuarterQ2 2025Date8/14/2025TimeDuring Market HoursConference Call DateN/AConference Call TimeN/AUpcoming EarningsBiocorrx's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Biocorrx Earnings HeadlinesBioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory BoardSeptember 10 at 8:53 AM | finance.yahoo.comBiocorrx (OTCMKTS:BICX) Stock Price Crosses Below 200 Day Moving Average - What's Next?September 1, 2026 | americanbankingnews.comTrump and Bernie agree on thisDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.September 12 at 1:00 AM | Porter & Company (Ad)BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market SupplyAugust 25, 2026 | finance.yahoo.comBioCorRx Inc.April 21, 2026 | marketwatch.comBioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant TechnologyMarch 11, 2026 | finance.yahoo.comSee More Biocorrx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email. Email Address About BiocorrxBiocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.View Biocorrx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseBlock Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
